- AptamiR successfully completed three rounds of Angels Financing and a Series A, raising a total of $7,000,000.
- AptamiR is now seeking to raise tranches of a $15-20M Series B financing while concurrently evaluating geographic licensing opportunities and strategic partnerships.
- Upcoming AptamiR Milestones
Activities during the next 3 years:
Pre- Clinical Activities:
- Selection of second generation of Oligonucleotide
Therapeutic (ONTs) Molecules targeting miRNA-22 and miRNA-515 in primary cultures
of human adipocytes
- Efficacy studies in mouse models of DIO, T2DM and NAFLD/NASH
- Acute and chronic toxicology studies in mice and monkeys
- Submission of pre-IND and IND dossiers
- Phase 1 Clinical studies of antagomirs and agomirs in cohorts of patients with obesity, diabesity and/or NAFLD